Zenas BioPharma, Inc. Common Stock (ZBIO) is a publicly traded Healthcare sector company. As of July 27, 2026, ZBIO trades at $32.71 with a market cap of $1.92B and a P/E ratio of -2.56. ZBIO moved +8.08% today. Year to date, ZBIO is -16.92%; over the trailing twelve months it is +86.21%. Its 52-week range spans $5.83 to $44.60. Analyst consensus is strong buy with an average price target of $41.40. Rallies surfaces ZBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for ZBIO shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $32.71 |
| Market Cap | $1.92B |
| P/E Ratio | -2.56 |
| EPS | $-11.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.60 |
| 52-Week Low | $5.83 |
| Volume | 501.31K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.00M |
| Net Income | $-156.99M |
| Gross Margin | 0.00% |
5 analysts cover ZBIO: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $41.40.